NASDAQ:VTVT vTv Therapeutics Q2 2026 Earnings Report $34.29 -1.08 (-3.05%) Closing price 08/10/2026 04:00 PM EasternExtended Trading$34.30 +0.01 (+0.03%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast vTv Therapeutics EPS ResultsActual EPS-$1.05Consensus EPS -$0.97Beat/MissMissed by -$0.08One Year Ago EPSN/AvTv Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.33 millionBeat/MissN/AYoY Revenue GrowthN/AvTv Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsvTv Therapeutics' Q3 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) vTv Therapeutics Earnings HeadlinesHC Wainwright Predicts Weaker Earnings for vTv TherapeuticsAugust 10 at 1:12 AM | americanbankingnews.comHC Wainwright Cuts vTv Therapeutics (NASDAQ:VTVT) Price Target to $42.00August 9 at 3:51 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.August 11 at 1:00 AM | Banyan Hill Publishing (Ad)vTv Therapeutics (NASDAQ:VTVT) Downgraded by Wall Street Zen to SellAugust 8 at 1:13 AM | americanbankingnews.comvTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 7, 2026 | markets.businessinsider.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 28, 2026 | globenewswire.comSee More vTv Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email. Email Address About vTv TherapeuticsvTv Therapeutics (NASDAQ:VTVT), Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties. The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies. Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.View vTv Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Caterpillar’s Blowout Quarter May Point to More Industrial WinnersSoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat5 Stocks the Market Rewarded After Strong Earnings ResultsQuantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of WarCloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Upcoming Earnings Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
